Ossica (Ibandronate Sodium Hydrate)

Ibandronate Sodium Hydrate, the active ingredient in Ossica, is a bisphosphonate presented as a oral tablet for osteoporosis treatment in postmenopausal women and men at risk of fracture. It works by inhibiting bone resorption and increasing bone mineral density.

GNH USA supplies Ossica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ossica is a bisphosphonate that acts on bone metabolism to reduce fracture risk in several skeletal conditions. - Post‑menopausal osteoporosis: improves the bone mineral density and lowers the risk of vertebral fractures. - Male osteoporosis: helps the increase the bone mass and decreases fracture incidence. - Glucocorticoid‑induced osteoporosis: mitigates the bone‑loss caused by long‑term steroid use. - Paget’s disease of the bone (though only in some regions off label use but recognised in guidelines for bisphosphonates).

Adverse reactions to ibandronate are reported across a spectrum of frequency.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia. - Musculoskeletal pain: transient bone, joint or muscle aches. - Flu‑like symptoms: mild fever, chills, fatigue. - Headache.

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Severe esophagitis or esophageal ulceration. - Acute renal impairment. - Hypocalcaemia. - Severe allergic reactions (anaphylaxis).

When prescribing ibandronate, clinicians should assess patient history and monitor for specific risks. - Renal function: evaluate baseline creatinine and adjust use if impairment present. - Calcium/Vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk. - Gastro‑intestinal health: advise patients to remain upright for at least 30 minutes after dosing. - Concomitant medications: review for drugs that may affect absorption or renal function. - Pregnancy and lactation: contraindicated; avoid use in women who are pregnant or breastfeeding. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Ibandronate may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid): - Antacids or supplements containing calcium, magnesium, aluminium, or iron: reduce ibandronate absorption. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) combined with high‑dose ibandronate: increase risk of gastrointestinal ulceration.\nModerate ...